Outlook Therapeutics Nears FDA Verdict on July 29 After Record Rally and Steep Correction

The countdown has begun for Outlook Therapeutics, with the U.S. Food and Drug Administration setting a binding decision date of July 29, 2026, for its experimental eye drug LYTENAVA™. The regulatory catalyst has already triggered a breathtaking surge in the company’s shares — followed by a sharp pullback that underscores just how feverish the market has become.

Over the past 30 trading days, the stock skyrocketed more than 620%, lifting year-to-date gains to 150% from a 52-week low of $0.16 hit in March. But the rally hit a speed bump this week, with shares shedding 10% as investors took profits. The sell-off was widely anticipated by technical analysts: the relative strength index had climbed to 76, deep in overbought territory, a classic setup for profit-taking. Even after the dip to $1.49, the stock remains well above its 50-day moving average, reflecting the enormous momentum that preceded the correction.

The underlying driver of this volatility is the FDA’s review of LYTENAVA™, a biologics license application for the treatment of neovascular age-related macular degeneration (nAMD). The agency designated the resubmission as a Class-1 review, meaning it has just two months to decide. This marks a dramatic turnaround from December 2025, when the FDA issued a complete response letter effectively rejecting the application. Outlook Therapeutics disputed the decision through the agency’s formal dispute resolution process, and the Office of New Drugs ultimately ruled that data from the NORSE-TWO and NORSE EIGHT studies, along with pharmacodynamic analyses, were sufficient to support efficacy without additional clinical trials. “This is a great outcome for patients and the retina community,” said CEO Bob Jahr. The company has already begun preparing for a potential U.S. commercial launch while the review proceeds.

Should investors sell immediately? Or is it worth buying Outlook Therapeutics?

Yet the euphoria on Wall Street stands in stark contrast to the company’s precarious financial position. At the end of the second quarter, Outlook held only $7.7 million in cash, relying on equity offerings, convertible notes, and restructured debt to stay afloat — a setup that carries persistent dilution risk for existing shareholders. Adding to the caution, BTIG downgraded the stock from Buy to Neutral, citing uncertainty around the U.S. approval and sluggish commercial traction in Europe, where LYTENAVA is already approved and launched. European sales in the second fiscal quarter of 2026 slipped roughly 10%, raising questions about the drug’s market reception even before the all-important U.S. decision.

With the FDA verdict now just weeks away, the binary nature of the outcome keeps the stock on a knife’s edge. A green light would make LYTENAVA the first and only FDA-approved ophthalmologic formulation of bevacizumab, giving Outlook a foothold in the lucrative retinal disease market. A rejection, however, would leave the company with a depleted balance sheet, a damaged share price, and no near-term catalyst. Until July 29, investors should brace for further violent swings as the market prices in both scenarios.